Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: Multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study)

International Journal of Clinical Practice

Volumn 65, Issue 1, 2011, Pages 54-63

  Verpooten, G A ^a,f   Aerts, A ^b   Coen, N ^b   Vancayzeele, S ^b   Hermans, C ^b   Bowles, J ^c   MacDonald, K ^c   Abraham, I ^c,d   Lee, C S ^c,e  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Novartis Pharma   (Belgium)

^c University of Arizona ^*  (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MULTICENTER STUDY; PATIENT; PATIENT COMPLIANCE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT FAILURE;

EID: 78650459102     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02562.x     Document Type: Article

References (41)

1. Kannel WB,. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85: 251-5.
2. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-7.
3. Lawes CM, Vander Hoorn S, Law MR, et al. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens 2006; 24: 423-30.
4. Lawes CM, Vander Hoorn S, Rodgers A,. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513-8.
5. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-9.
6. Lawes CM, Vander Hoorn S, Law MR, et al. Blood pressure and the global burden of disease 2000. Part 1: estimates of blood pressure levels. J Hypertens 2006; 24: 413-22.
7. Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-62.
8. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-63.
9. Fagard RH, Van Den Enden M, Leeman M, Warling X,. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297-302.
10. Lloyd-Jones DM, Evans JC, Levy D,. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294: 466-72.
11. Degli Esposti E, Di Martino M, Sturani A, et al. Risk factors for uncontrolled hypertension in Italy. J Hum Hypertens 2004; 18: 207-13.
12. Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162: 413-20.
13. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006; 47: 345-51.
14. Gasse C, Hense HW, Stieber J, et al. Assessing hypertension management in the community: trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-1995. J Hum Hypertens 2001; 15: 27-36.
15. Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007; 55: 1056-65.
16. Wang YR, Alexander GC, Stafford RS,. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007; 167: 141-7.
17. Kjeldsen SE, Naditch-Brule L, Perlini S, et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008; 26: 2064-70.
18. Jokisalo E, Kumpusalo E, Enlund H, et al. Factors related to non-compliance with antihypertensive drug therapy. J Hum Hypertens 2002; 16: 577-83.
19. Van Wijk BL, Klungel OH, Heerdink ER, De Boer A,. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23: 2101-7.
20. Van der Niepen P, Woestenburg A, Brie H, et al. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study). Ann Pharmacother 2009; 43: 849-61.
21. Frampton JE, Curran MP,. Aliskiren: a review of its use in the management of hypertension. Drugs 2007; 67: 1767-92.
22. Stanton A, Jensen C, Nussberger J, O'Brien E,. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-43.
23. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-8.
24. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-63.
25. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-99.
26. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217-26.
27. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-8.
28. Drummond W, Munger MA, Rafique Essop M, et al. Antihypertensive efficacy of the oral direct Renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007; 9: 742-50.
29. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111: 697-716.
30. Verbeke G, Molenberghs G,. Linear Mixed Models for Longitudinal Data. New York, NY: Springer-Verlag, 2000.
31. Rabe-Hesketh S, Skrondal A,. Multilevel and Longitudinal Modeling Using Stata, 2nd edn. College Station, Texas, USA: Stata Press, 2008.
32. Volpe M, Tocci G,. 2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. J Hypertens 2009; 27 (Suppl. 3): S3-11.
33. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007; 14 (Suppl. 2): S1-113.
34. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58.
35. Blacher J, Evans A, Arveiler D, et al. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. J Hum Hypertens 2010; 24: 19-26.
36. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120: 1598-605.
37. Heisler M, Hogan MM, Hofer TP, et al. When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation 2008; 117: 2884-92.
38. Palatini P, Jung W, Shlyakhto E, et al. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24: 93-103.
39. Messerli FH, Williams B, Ritz E,. Essential hypertension. Lancet 2007; 370: 591-603.
40. Grossman E, Messerli FH,. Hypertension and diabetes. Adv Cardiol 2008; 45: 82-106.
41. American Heart Association. Get With The Guidelines. 2009 [cited 22 December, 2009]; Available from http://www.americanheart.org/presenter.jhtml? identifier=1165